Dactinomycin
Specifications
50-76-0CAS Number
200-063-6EC Number
2-amino-4,6-dimethyl-3-oxo-1-N,9-N-bis[(3R,6S,7R,10S,16S)-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-3,10-di(propan-2-yl)-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]phenoxazine-1,9-dicarboxamideIUPAC Name
C62H86N12O16Chemical Formula
1255.4 g/molMolecular Weight
DACTINOMYCIN; actinomycin D; Actinomycin C1; Cosmegen; Actinomycin IV; Meractinomycin; 50-76-0; Oncostatin K; Actinomycin I1; Actinomycin X1; Dactinomicina; Dactinomycine; Dactinomycinum; Cosmegen Lyovac; Lyovac-Cosmegen; Chounghwamycin B; ActD; Dilactone actinomycin D acid; ACTINOMYCIN-D; Actinomycin I; Dactinomycin D; Actinomycin X 1; Actinomycin A IV; DTXSID9020031; NCI-C04682; Actinomycin D (Dactinomycin); Lyovac cosmegen; Actinomycin Aiv; GNF-Pf-2290; NSC 3053; 1CC1JFE158; NSC-3053; DTXCID5031; Dilactone actinomycindioic D acid; CHEBI:27666; 2-amino-4,6-dimethyl-3-oxo-1-N,9-N-bis[(3R,6S,7R,10S,16S)-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-3,10-di(propan-2-yl)-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]phenoxazine-1,9-dicarboxamide; HBF 386; Actinomycindioic D acid, dilactone; 2-amino-N,N'-bis(hexadecahydro-2,5,9-trimethyl-6,13-bis(1-methylethyl)-1,4,7,11,14-pentaoxo-1H-pyrrolo(2,1-i)(1,4,7,10,13)oxatetra-azacyclohexadecin-10-yl)-4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-dicarboxamide; Stereoisomer of N,N'-((2-amino-4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-diyl)bis(carbonylimino(2-(1-hydroxyethyl)-1-oxo-2,1-ethanediyl)imino(2-(1-methylethyl)-1-oxo-2,1-ethanediyl)-1,2-pyrrolidinediylcarbonyl(methylimino) (1-oxo-2,1-ethanediyl)))bis(N-methyl-L-valine)di-xi-lactone; NSC3053; LyovacCosmegen; 3H-Phenoxazine, actinomycin D deriv.; Lyovac, Cosmegen; 3H-PHENOXAZINE-1,9-DICARBOXAMIDE, 2-AMINO-N,N'-BIS(HEXADECAHYDRO-6,13-DIISOPROPYL-2,5,9-TRIMETHYL-1,4,7,11,14-PENTAOXO-1H-PYRROLO(2,1-I)(1,4,7,10,13)OXATETRAAZACYCLOHEXADECIN-10-YL)-4,6-DIMETHYL-3-OXO-; N,N'-((2-AMINO-4,6-DIMETHYL-3-OXO-3H-PHENOXAZINE-1,9-DIYL)-BIS(CARBONYLIMINO(2-HYDROXYPROPYLIDENE)CARBONYLIMINOISOBUTYLIDENECARBONYL-1,2-PYRROLIDINEDIYLCARBONYL(METHYLIMINO)METHYLENECARBONYL))BIS(N-METHYL-L-VALINE) DILACTONE; 1-N,9-N-bis((6S,9R,10S,13R,18aS)-2,5,9-trimethyl-1,4,7,11,14-pentaoxo-6,13-bis(propan-2-yl)-hexadecahydro-1H-pyrrolo(2,1-i)1-oxa-4,7,10,13-tetraazacyclohexadecan-10-yl)-2-amino-4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-dicarboxamide; 1-N,9-N-bis[(6S,9R,10S,13R,18aS)-2,5,9-trimethyl-1,4,7,11,14-pentaoxo-6,13-bis(propan-2-yl)-hexadecahydro-1H-pyrrolo[2,1-i]1-oxa-4,7,10,13-tetraazacyclohexadecan-10-yl]-2-amino-4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-dicarboxamide; 2-amino-4,6-dimethyl-3-oxo-1-N,9-N-bis((3R,6S,7R,10S,16S)-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-3,10-di(propan-2-yl)-8-oxa-1,4,11,14-tetrazabicyclo(14.3.0)nonadecan-6-yl)phenoxazine-1,9-dicarboxamide; RefChem:54926; L01DA01; 2-amino-4,6-dimethyl-3-oxo-1-N,9-N-bis(7,11,14-trimethyl-2,5,9,12,15-pentaoxo-3,10-di(propan-2-yl)-8-oxa-1,4,11,14-tetrazabicyclo(14.3.0)nonadecan-6-yl)phenoxazine-1,9-dicarboxamide; Actinomycin-(thr-val-pro-sar-meval); 2-bis(Cyclo(N-methyl-L-valyl-sarcosyl-L-prolyl-D-valyl-L-threonyl))-1,9 dimethyl-4,6 3H-phenoxazinone-3; 200-063-6; 1H-Pyrrolo(2,1-i)(1,4,7,10,13)oxatetraazacyclohexadecine, cyclic peptide deriv.; ACT D; Dactinomycine [INN-French]; Dactinomycinum [INN-Latin]; Dactinomicina [INN-Spanish]; Actinomycin 7; MFCD00005033; MLS001424196; Actinomycin; Acto-D; Actinomycin C(sub1); NCGC00161622-02; Actinomycin I(sub 1); SMR000469227; Actinomycin 11 cosmegen; C62H86N12O16; CCRIS 9; HSDB 3220; Antibiotic from Streptomyces parvullus; Actinomycin-(threo-val-pro-sar-meval); CAS-50-76-0; ACT [antibiotic]; X 97; 2-amino-N1,N9-bis[(3R,6S,7R,10S,16S)-3,10-diisopropyl-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]-4,6-dimethyl-3-oxo-phenoxazine-1,9-dicarboxamide; AD (VAN); GNF-PF-1977; UNII-1CC1JFE158; NSC191297; Actinomycin D?; Glycopeptide, 4a; 2-amino-4,6-dimethyl-3-oxo-N,N'-bis[(6S,9R,10S,13R,18aS)-2,5,9-trimethyl-6,13-bis(1-methylethyl)-1,4,7,11,14-pentaoxohexadecahydro-1H-pyrrolo[2,1-i][1,4,7,10,13]oxatetraazacyclohexadecin-10-yl]-3H-phenoxazine-1,9-dicarboxamide; Dactinomycin [USAN:USP:INN:BAN]; EINECS 200-063-6; AI3-26374; DACTINOMYCIN [MI]; DACTINOMYCIN [INN]; UPCMLD-DP055; DACTINOMYCIN [HSDB]; DACTINOMYCIN [USAN]; SCHEMBL3844; ACTINOMYCIN D [JAN]; CHEMBL1554; DACTINOMYCIN [VANDF]; ACTINOMYCIN D [IARC]; DACTINOMYCIN [MART.]; DACTINOMYCIN [USP-RS]; DACTINOMYCIN [WHO-DD]; DACTINOMYCIN [WHO-IP]; cid_457193; orb3023229; ACTINOMYCIN D [WHO-IP]; UPCMLD-DP055:001; UPCMLD-DP055:002; BDBM43866; DACTINOMYCIN [ORANGE BOOK]; HMS2052O17; DACTINOMYCIN [USP MONOGRAPH]; Tox21_111997; Tox21_202482; BDBM50089528; s8964; DACTINOMYCINUM [WHO-IP LATIN]; AKOS030228553; Tox21_111997_1; CCG-101134; DB00970; NC00384; NCGC00090796-01; NCGC00161622-01; NCGC00260031-01; NCGC00271789-02; 3H-Phenoxazine-1,9-dicarboxamide, 2-amino-N,N'-bis(hexadecahydro-2,5,9-trimethyl-6,13-bis(1-methylethyl)-1,4,7,11,14-pentaoxo-1H-pyrrolo(2,1-i)(1,4,7,10,13)oxatetra-azacyclohexadecin-10-yl)-4,6-dimethyl-3-oxo-; BP-25384; N1,N9-bis[(6S,9R,10S,13R,18aS)-2,5,9-trimethyl-1,4,7,11,14-pentaoxo-6,13-bis(propan-2-yl)-hexadecahydro-1H-pyrrolo[2,1-i]1-oxa-4,7,10,13-tetraazacyclohexadecan-10-yl]-2-amino-4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-dicarboxamide; Specific stereoisomer of N,N'-((2-amino-4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-diyl)-bis(carbonylimino(2-hydroxypropylidene)carbonyliminoisobutylidenecarbonyl-1,2-pyrrolidinediylcarbonyl(methylimino)methylenecarbonyl))bis(N-methyl-L-valine) dilactone; A0977; A11553; AB00514445-05; EN300-7480748; Q186127; SR-01000763161; SR-01000763161-4; Actinomycin D, from Streptomyces sp., >=95% (HPLC); Actinomycin D, from Streptomyces sp., ~98% (HPLC); BRD-K70578146-001-01-8; BRD-K70578146-001-04-2; BRD-K70578146-001-06-7; Dactinomycin, United States Pharmacopeia (USP) Reference Standard; Actinomycin D, for fluorescence, >=90% (HPLC), from Streptomyces sp.; Actinomycin D, from Streptomyces sp., suitable for cell culture, >=95%; 2-amino-4,6-dimethyl-3-oxo-1-N,9-N-bis-[(18aS)-10c,14,17-trimethyl-5,8,12,15,18-pentaoxo-6c,13t-di(propan-2-yl)-18ar-hexadecahydro-1H-pyrrolo[2,1-i][1,4,7,10,13]oxatetraazacyclohexadecin-9c-yl]-3H-phenoxazine-1,9-dicarboxamide; 2-Amino-4,6-dimethyl-3-oxo-N~1~,N~9~-bis(6S,9R,10S,13R,18aS)[2,5,9-trimethyl-1,4,7,11,14-pentaoxo-6,13-di(propan-2-yl)hexadecahydro-1H-pyrrolo[2,1-i][1,4,7,10,13]oxatetraazacyclohexadecin-10-yl]-3H-phenoxazine-1,9-dicarboxamide; 2-amino-4,6-dimethyl-3-oxo-N1,N9-bis[(3R,6S,7R,10S,16S)-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-3,10-di(propan-2-yl)-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]phenoxazine-1,9-dicarboxamide; 2-amino-N,N''''''''-bis[(3R,6S,7R,10S,16S)-3,10-diisopropyl-2,5,9,12,15-pentaketo-7,11,14-trimethyl-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]-3-keto-4,6-dimethyl-phenoxazine-1,9-dicarboxamide; 2-amino-N,N''''-bis[(3R,6S,7R,10S,16S)-3,10-diisopropyl-2,5,9,12,15-pentaketo-7,11,14-trimethyl-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]-3-keto-4,6-dimethyl-phenoxazine-1,9-dicarboxamide; 2-amino-N,N''-bis[(3R,6S,7R,10S,16S)-3,10-diisopropyl-2,5,9,12,15-pentaketo-7,11,14-trimethyl-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]-3-keto-4,6-dimethyl-phenoxazine-1,9-dicarboxamide; 2-azanyl-4,6-dimethyl-3-oxidanylidene-N1,N9-bis[(3R,6S,7R,10S,16S)-7,11,14-trimethyl-2,5,9,12,15-pentakis(oxidanylidene)-3,10-di(propan-2-yl)-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]phenoxazine-1,9-dicarboxamide; 3H-Phenoxazine-1,9-dicarboxamide, 2-amino-N,N'-bis[(6S,9R,10S,13R,18aS)-hexadecahydro-2,5,9-trimethyl-6,13-bis(1-methylethyl)-1,4,7,11,14-pentaoxo-1H-pyrrolo[2,1-i][1,4,7,10,13]oxatetraazacyclohexadecin-10-yl]-4,6-dimethyl-3-oxo-Synonyms
